Desferal Mesylate is a chelating agent based on Deferoxamine. Deferoxamine is a substance which binds with iron in the bloodstream. The resulting combination is excreted through urine. Desferal Mesylate serves to remove the excess iron from the body and thus lessening or altogether preventing the damage it may cause otherwise. Desferal may only be administered under the supervision of a specialized health care professional.
The removal of excess iron from the organism by administering Desferal Mesylate is required in the case of patients suffering from certain medical conditions. For example, it is employed in some cases of anemia when the patient receives numerous blood transfusions or in the case of acute iron poisoning (particularly in the case of infants and small children). Desferal Mesylate may be employed in other cases as well. If you are unsure why you are being administered Desferal, it is best that you consult with your personal physician or the supervising health care professional.
You should not start a treatment with Desferal Mesylate if you are allergic to Desferal or to Deferoxamine, or if you have a known hypersensitivity to similar medical products. It is best that you let the prescriber know if you are allergic to any substances (including foods, dyes or preservatives) before he or she makes the decision regarding the medication best suited to your case.
Desferal Mesylate should not be prescribed for prolonged periods of time in patients younger than 3 years of age. Typically, young patients are more susceptible to developing vision or hearing impairment with prolonged or high-dose treatment with Desferal. Caution should also be employed in the treatment of elderly patients. Desferal may not be suitable for use during pregnancy. If you are pregnant and require therapy with this type of medicine it is best to consult your personal physician regarding the risks and benefits of the treatment.
Desferal Mesylate may only be administered under the strict supervision of a specialized health care professional. The medicine is administered to the patient under the form of an intravenous or intramuscular injection, or in some cases as a subcutaneous injection. The exact administration specifications will be determined from one case to another depending on a number of factors that are specific to the patient's situation. The treatment duration will also depend on the severity of the condition and the patient's response to the treatment, as well as on a number of other factors.
The exact Desferal Mesylate dosage will be determined by the prescriber based on a number of factors that are particular to each case, in order to obtain the best therapeutic results from the treatment. On average, for acute iron toxicity the initial adult dosage is of 90 mg per kg of body weight followed by 45 mg per kg doses administered at equal time intervals (four to twelve hours must pass between the doses) through intramuscular injections. If the medicine is administered through IV, the dosage is of 15 mg per kg per hour administered every eight hours. In the case of children younger than 3, the typical dosage is of 15 mg per kg per hour, administered intravenously.
In the case of chronic iron toxicity, the average Desferal Mesylate daily dosage is of 500 mg to 1 g injected into a muscle.
An overdose with Desferal Mesylate may lead to severe consequences, such as hearing or visual impairment. However, due to the fact that administration of Desferal may only be performed under the strict supervision of an authorized health care professional in hospital settings, it is highly unlikely for a larger quantity of the medicine to be administered.
If you have any concern that you may be affected by an overdose with Desferal Mesylate, you should immediately consult with the supervising health care professional.
If you are being administered the Desferal Mesylate doses in a hospital or a clinic, it is highly unlikely to miss any doses of the medicine. However, if you are following therapy with Desferal in an outpatient clinic and miss one of your scheduled appointments, it is strongly suggested to contact your personal health care professional and set another appointment as soon as possible. Missing any of your Desferal Mesylate doses may have severe consequences and should be avoided.
Desferal Mesylate is likely to cause the patient's urine to change color to orange-rose. Several other side effects may appear during your therapy with Desferal Mesylate. The side effects may include, but are not limited to vision problems, seizures, wheezing, tachycardia, hearing impairment, rashes, hives or pain at the site of the injection. Less commonly, diarrhea, urination problems, fever and cramps have been noted. Other side effects than listed here may appear as well. It is best to consult your personal physician as soon as possible if you experience any uncommon signs or symptoms.
There are several drugs and medicines that may interact with Desferal Mesylate leading to the appearance of unwanted effects or to a change in the effects of either of the medical products. As such, it is best that you inform your prescriber of any other drugs you are currently taking before starting a treatment with Desferal. Also, it is best that you inform your personal health care professional before starting to take any other medicines while following a therapy course with Desferal Mesylate.
One of the most common substances that Desferal interacts with is ascorbic acid (Vitamin C). Desferal should never be prescribed during your therapy with Desferal Mesylate unless your personal health care professional specifically instructs you to do so, as the combination may cause severe tissue damage - especially in elderly patients.
Other Brand Names
In some countries Desferal may also be known as: